Press Release: MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones11-13

Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in MetALD and ALD

Appointed Sarah Browne, M.D., as Chief Medical Officer to Help Lead the Next Stage of Clinical Development for DA-1726 and Vanoglipel

Full Data From the Phase 1 Parts 3A and 3B Expected in the First Quarter of 2027

CAMBRIDGE, Mass., Nov. 13, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate strategic update.

"The positive interim results from our Phase 1 Part 3B study of DA-1726, a novel oxyntomodulin $(OXM)$ analog and dual GLP-1/glucagon receptor agonist, were recently highlighted in an oral presentation at the Precision Liver Symposium. We believe these findings provide important clinical support for DA-1726's potential to treat metabolic dysfunction and alcohol-associated liver disease (MetALD), as well as alcohol-associated liver disease $(ALD)$," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "Most notably, after approximately 16 weeks, we observed a 68.1% placebo-adjusted reduction in liver fat, with all five of the participants with baseline steatosis achieving MRI-PDFF below 5%. These findings were accompanied by 13.5% placebo-adjusted weight loss, significant reductions in adipose tissue and relative preservation of lean tissue. Recently reported additional interim data also demonstrated a statistically significant 1.47 mg/dL placebo-adjusted reduction in uric acid after 16 weeks of treatment, further supporting DA-1726's liver-focused cardiometabolic profile. Based on these results, we are planning a 48-week Phase 2 study in up to 150 subjects with MetALD and ALD, targeted to begin in the second half of 2027. We also recently hosted an invitation-only KOL dinner during AASLD's The Liver Meeting 2026 featuring Dr. Rohit Loomba, a member of our Scientific Advisory Board. The event provided a valuable opportunity to gather leading experts in the field to discuss the evolving treatment landscape in MetALD and the significant unmet medical need we hope to address."

Mr. Kim continued, "Last month, we also expanded our clinical leadership team with the appointment of Sarah Browne, M.D., as Chief Medical Officer. Sarah brings more than 20 years of experience spanning clinical development, regulatory science and clinical medicine, including leading the development of pemvidutide, a dual GLP-1/glucagon receptor agonist, through Phase 2 and establishing Phase 3 development strategies. Her extensive experience developing therapies for metabolic and liver diseases will be particularly valuable as we prepare to move DA-1726 into Phase 2 development in MetALD and ALD. In parallel, we continue to advance vanoglipel, our G-protein-coupled receptor 119 (GPR119) agonist, in combination with resmetirom for MASH, with a Phase 2a proof-of-concept study targeted to begin in the first half of 2027."

Third Quarter 2026 and Subsequent Highlights

   -- November 2026: Announced additional positive Phase 1 Part 3B interim data 
      demonstrating a statistically significant 1.47 mg/dL placebo-adjusted 
      reduction in uric acid after 16 weeks of treatment with DA-1726 (p<0.001), 
      further supporting its liver-focused cardiometabolic profile. 
 
   -- November 2026: Announced the presentation of preclinical data on DA-1726 
      at ObesityWeek 2026 in a poster entitled, DA-1726 Demonstrates Comparable 
      Weight Loss and Distinct Metabolic Profile Compared With Retatrutide. 
 
   -- November 2026: Presented positive DA-1726 Phase 1 Part 3B interim data in 
      an oral presentation at the Precision Liver Symposium, demonstrating a 
      68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted 
      weight loss at Day 109, with all five participants with baseline 
      steatosis achieving MRI-PDFF below 5%. Announced plans to initiate a 
      48-week Phase 2 study in MetALD and ALD. 
 
   -- October 2026: Appointed Sarah Browne, M.D., as Chief Medical Officer to 
      provide clinical and regulatory leadership as MetaVia advances DA-1726 
      and vanoglipel through their next stages of development. 
 
   -- September 2026: Announced preclinical tissue distribution findings for 
      DA-1726 showing the highest exposure in adipose tissue and prolonged 
      tissue retention, providing biological support for the reductions in 
      waist circumference observed clinically and DA-1726's once-weekly dosing 
      profile. 
 
   -- July 2026: Announced the completion of dose titration in the 16-week 
      Phase 1 Part 3 study of DA-1726, with all active patients successfully 
      reaching the highest planned dose levels of 48 mg and 64 mg. 

Anticipated Clinical Milestones

   -- DA-1726 in MetALD and ALD: 
 
          -- Full data from Phase 1 Parts 3A and 3B expected in the first 
             quarter of 2027. 
 
          -- Initiation of a 48-week, non-biopsy Phase 2 study in up to 150 
             subjects with MetALD and ALD is targeted for the second half of 
             2027. 
 
   -- Vanoglipel (DA-1241) in MASH: 
 
          -- MetaVia is currently working to schedule an End-of-Phase 2 meeting 
             with the FDA before the end of 2026 to discuss the clinical 
             development pathway for vanoglipel in combination with resmetirom. 
 
          -- Initiation of a randomized, 12-week Phase 2a non-biopsy 
             proof-of-concept study of vanoglipel in combination with 
             resmetirom is targeted for the first half of 2027. 

Third Quarter Financial and Operating Results

   -- Research and Development (R&D) Expenses were approximately $2.6 million 
      for the third quarter ended September 30, 2026, as compared to 
      approximately $1.9 million for the third quarter ended September 30, 
      2025. The increase of approximately $0.7 million was primarily 
      attributable to higher direct R&D expenses related to DA-1726 product 
      development, partially offset by $0.2 million in lower indirect 
      consulting expenses.R&D expenses were approximately $8.2 million for the 
      nine months ended September 30, 2026, as compared to approximately $6.6 
      million for the nine months ended September 30, 2025. The approximately 
      $1.6 million increase was primarily attributable to $2.0 million in 
      higher direct R&D expenses related to DA-1726 product development, 
      partially offset by (i) $0.2 million in lower indirect consulting 
      expenditures and (ii) $0.2 million in lower direct R&D expenses related 
      to vanoglipel product development. 
 
   -- General and Administrative (G&A) Expenses were approximately $2.1 million 
      for the third quarter ended September 30, 2026, as compared to 
      approximately $1.6 million for the third quarter ended September 30, 
      2025. The approximately $0.5 million increase was primarily attributable 
      to (i) $0.2 million in higher legal and professional fees, (ii) $0.2 
      million in higher consulting expenditures and (iii) $0.1 million in 
      higher employee compensation and benefits. G&A expenses were 
      approximately $5.9 million for the nine months ended September 30, 2026, 
      as compared to approximately $5.1 million for the nine months 
      ended September 30, 2025. The approximately $0.8 million increase was 
      primarily attributable to (i) approximately $0.3 million in higher 
      consulting expenditures, (ii) approximately $0.2 million in higher legal 
      and professional fees, (iii) approximately $0.1 million in higher 
      employee compensation and benefits costs and (iv) $0.2 million in higher 
      other G&A expenses, which was primarily related to higher franchise tax 
      expenses. 
 
   -- Total Operating Expenses were approximately $4.7 million for the third 
      quarter ended September 30, 2026, compared to approximately $3.5 million 
      for the third quarter ended September 30, 2025. The approximately $1.2 
      million increase was primarily attributable to higher R&D and G&A 
      expenses.Total operating expenses were approximately $14.1 million for 
      the nine months ended September 30, 2026, compared to approximately $11.7 
      million for the nine months ended September 30, 2025. The approximately 
      $2.4 million increase was primarily attributable to higher R&D and G&A 
      expenses for the nine months ended September 30, 2026. 
 
   -- Total Other Income was approximately $0.1 million for the third quarter 
      ended September 30, 2026, unchanged from the third quarter ended 
      September 30, 2025.Total other income was approximately $0.3 million for 
      the nine months ended September 30, 2026, as compared to approximately 
      $0.6 million for the nine months ended September 30, 2025. The 
      approximately $0.3 million decrease was primarily attributable to (i) 
      $0.1 million in lower gain from change in fair value of warrant 
      liabilities and (ii) $0.2 million in lower interest income, net, due to 
      lower balances of cash and cash equivalents and lower interest rates. 
 
   -- Net Loss was $4.6 million, or $0.69 per basic and diluted share, for the 
      third quarter ended September 30, 2026, based on 6,679,250 weighted 
      average shares of common stock outstanding, compared with a net loss of 
      $3.4 million, or $1.52 per basic and diluted share, based on 2,219,625 
      weighted average shares of common stock outstanding for the third quarter 
      ended September 30, 2025.Net loss was approximately $13.8 million, 
      or $2.36 per basic and diluted share for the nine months ended September 
      30, 2026, based on 5,830,258 weighted average shares of common stock 
      outstanding, compared with a net loss of approximately $11.0 million, 
      or $6.93 per basic and diluted share, based on 1,592,484 weighted average 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment